IndustryCompany release

Iradimed third-quarter revenue rises 14% to $24.2m on 3870 MR IV pump rollout

🇺🇸 Iradimed Corp (IRMD) · Fri 30 Oct 2026

The MRI-compatible infusion pump maker also lifted net income 17% to $6.5m, narrowed its full-year revenue guidance and declared a $0.20 quarterly dividend.

Iradimed, which makes MRI-compatible intravenous infusion pumps and patient vital signs monitors, reported results for the third quarter of 2026 on 30 October. Revenue grew 14% year on year to $24.2m.

Net income rose 17% to $6.5m. The company attributed the performance to the rollout of its 3870 MR IV pump.

Iradimed narrowed its full-year 2026 revenue guidance to a range of $91.6m to $93.1m. The summary available does not say what the previous range was, so the scale of the adjustment cannot be assessed here.

The board also declared a quarterly dividend of $0.20 per share, payable on 27 November 2026. No further detail on the results, such as regional sales, margins or the pace of the 3870 MR launch, was available for this report.

What it means for your team

  • Market-access and procurement teams in MR-conditional settings should note that the 3870 MR IV pump is now a main growth driver for Iradimed.
  • The narrowed guidance range of $91.6m to $93.1m gives a clearer view of the company's expected full-year revenue.
  • Quality and vigilance teams at hospitals adopting new MR-compatible pumps may wish to confirm device-specific training and incident reporting arrangements; the source does not describe any safety or regulatory issue.

Company's press release (SEC filing): Iradimed Corp ↗

Article written by VigiEye from the official source (Iradimed Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →